ArticleJournal of advanced research2026
Long non-coding RNA antisense of insulin-like growth factor 2 receptor promotes osteogenic differentiation by enhancing runt-related transcription factor 2 translation: A potential therapeutic target for osteoporosis.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human lncRNA, hLinfRNA7 (IDO1-AS) Regulates Cytokine Expression, Tryptophan Catabolism, and Inflammatory Response in Macrophage.Molecular and cellular biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOsteoporosis is a chronic metabolic disorder characterized by progressive bone loss and increased susceptibility to fractures, for which there is currently no curative treatment that can fully reverse or eliminate the disease.
objectivesThis study aims to elucidate the regulatory role of antisense of insulin-like growth factor 2 receptor non-protein coding RNA (AIRN) in osteogenesis and the pathogenesis of osteoporosis.
methodsMultiple in vivo models of osteoporosis, including tail suspension, ovariectomy, and natural aging, were employed to evaluate the impact of Airn knockout or overexpression on bone formation. A comprehensive array of in vitro assays, including alkaline phosphatase staining, quantitative PCR, Western blotting, bioinformatics analysis, mRNA stability assays, RNA fluorescence in situ hybridization, RNA immunoprecipitation, and luciferase reporter assays, were conducted to investigate the functional mechanisms of AIRN.
resultsWe found that Airn is highly enriched in osteogenic lineage cells, significantly upregulated during osteoblast differentiation, and notably downregulated in osteoporotic bone tissue. In vivo, Airn knockout led to impaired bone formation and aggravated bone loss across all three osteoporosis models. Furthermore, AAV9-mediated intratibial overexpression of Airn significantly promoted bone formation and attenuated tail suspension-induced osteoporosis. In vitro, Airn overexpression enhanced the expression of osteogenic marker genes, whereas AIRN knockdown suppressed their expression. Mechanistically, Airn binds to polypyrimidine tract binding protein 1 (PTBP1) and facilitates internal ribosome entry site (IRES)-mediated translation of runt-related transcription factor 2 (Runx2) by enhancing IRES activity within the 5' untranslated region of Runx2 mRNA. Additionally, our data demonstrated that the upregulation of Airn during osteogenic differentiation is orchestrated by RUNX1.
conclusionOur findings identify Airn as a critical regulator of osteoblast differentiation. Its regulatory effect on Runx2 translation via PTBP1 highlights a novel mechanism underlying osteogenesis and suggests that Airn may serve as a potential therapeutic target for the treatment of osteoporosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.